UPDATE: Goldman Reiterates Sell On Clovis Oncology, Lowers Target To $3 As Firm Sees 'risk to longer term consensus estimates that embed meaningful growth driven from Rubraca use in prostate cancer and frontline/combo use with PD-1s'